Search results

Showing 1 – 10 of 10 results.
Curated
Restricted

Arrestee Drug Abuse Monitoring (ADAM) Program in the United States, 2001 (ICPSR 3688)

Released/updated on: 2006-03-30
Geographic coverage: North Carolina, Oklahoma City, Detroit, Charlotte, Indiana, Tucson, Albuquerque, Spokane, Utah, San Jose, New York City, San Diego, Arizona, Las Vegas, Sacramento, Seattle, California, Pennsylvania, Tulsa, Laredo, Iowa, Illinois, Texas, Portland (Oregon), Indianapolis, Oregon, United States, Oklahoma, Alabama, Cleveland, Washington, Nebraska, Albany (New York), Omaha, Minneapolis, Colorado, Honolulu, Missouri, New Orleans, Alaska, Phoenix, Denver, Salt Lake City, Dallas, Nevada, Des Moines, San Antonio, Chicago, Hawaii, Minnesota, Kansas City (Missouri), New York (state), Birmingham, Michigan, New Mexico, Louisiana, Anchorage, Ohio, Philadelphia
Time period: 2001-01-01--2001-12-31
The goal of the Arrestee Drug Abuse Monitoring (ADAM) Program is to determine the extent and correlates of illicit drug use in the population of booked arrestees in local areas. Data were collected in 2001 at four separate times (quarterly) during the year in 33 metropolitan areas in the United States. The ADAM program adopted a new instrument in 2000 in adult booking facilities for male (Part 1) and female (Part 2) arrestees. Data from arrestees in juvenile detention facilities (Part 3) continued to use the juvenile instrument from previous years, extending back through the DRUG USE FORECASTING series (ICPSR 9477). The ADAM program in 2001 also continued the use of probability-based sampling for male arrestees in adult facilities, which was initiated in 2000. Therefore, the male adult sample includes weights, generated through post-sampling stratification of the data. For the adult files, variables fell into one of eight categories: (1) demographic data on each arrestee, (2) ADAM facesheet (records-based) data, (3) data on disposition of the case, including accession to a verbal consent script, (4) calendar of admissions to substance abuse and mental health treatment programs, (5) data on alcohol and drug use, abuse, and dependence (6) drug acquisition data covering the five most commonly used illicit drugs, (7) urine test results, and (8) weights. The juvenile file contains demographic variables and arrestee's self-reported past and continued use of 15 drugs, as well as other drug-related behaviors.
Curated
Restricted

Arrestee Drug Abuse Monitoring (ADAM) Program in the United States, 2002 (ICPSR 3815)

Released/updated on: 2006-03-30
Geographic coverage: North Carolina, Oklahoma City, Charlotte, Indiana, Tucson, Albuquerque, Spokane, Utah, San Jose, New York City, San Diego, Arizona, Las Vegas, Sacramento, Seattle, California, Washington, District of Columbia, Pennsylvania, Tulsa, Laredo, Iowa, Illinois, Texas, Portland (Oregon), Georgia, Indianapolis, Oregon, United States, Oklahoma, Rio Arriba, Alabama, Cleveland, Washington, Nebraska, Albany (New York), Omaha, Minneapolis, Woodbury, Atlanta, Colorado, Honolulu, New Orleans, Alaska, Phoenix, Denver, Salt Lake City, Dallas, Nevada, Des Moines, San Antonio, Chicago, Hawaii, Minnesota, New York (state), Birmingham, New Mexico, Louisiana, Anchorage, Ohio, Los Angeles, Philadelphia
Time period: 2002-01-01--2002-12-31
The goal of the Arrestee Drug Abuse Monitoring (ADAM) Program is to determine the extent and correlates of illicit drug use in the population of booked arrestees in local areas. Data were collected in 2002 at four separate times (quarterly) during the year in 36 metropolitan areas in the United States. The ADAM program adopted a new instrument in 2000 in adult booking facilities for male (Part 1) and female (Part 2) arrestees. Data from arrestees in juvenile detention facilities (Part 3) continued to use the juvenile instrument from previous years, extending back through the DRUG USE FORECASTING series (ICPSR 9477). The ADAM program in 2002 also continued the use of probability-based sampling for male arrestees in adult facilities, which was initiated in 2000. Therefore, the male adult sample includes weights, generated through post-sampling stratification of the data. For the adult files, variables fell into one of eight categories: (1) demographic data on each arrestee, (2) ADAM facesheet (records-based) data, (3) data on disposition of the case, including accession to a verbal consent script, (4) calendar of admissions to substance abuse and mental health treatment programs, (5) data on alcohol and drug use, abuse, and dependence, (6) drug acquisition data covering the five most commonly used illicit drugs, (7) urine test results, and (8) weights. The juvenile file contains demographic variables and arrestee's self-reported past and continued use of 15 drugs, as well as other drug-related behaviors.
Curated
Restricted

Arrestee Drug Abuse Monitoring (ADAM) Program in the United States, 2003 (ICPSR 4020)

Released/updated on: 2006-03-30
Geographic coverage: North Carolina, Oklahoma City, Charlotte, Indiana, Tucson, Albuquerque, Spokane, Utah, San Jose, New York City, San Diego, Arizona, Las Vegas, Boston, Sacramento, Seattle, California, Florida, Pennsylvania, Tulsa, Iowa, Illinois, Texas, Portland (Oregon), Georgia, Tampa, Indianapolis, Oregon, United States, Oklahoma, Rio Arriba, Alabama, Cleveland, Washington, Nebraska, Albany (New York), Omaha, Minneapolis, Woodbury, Atlanta, Massachusetts, Colorado, Honolulu, New Orleans, Alaska, Phoenix, Denver, Salt Lake City, Dallas, Nevada, Des Moines, District of Columbia, San Antonio, Chicago, Hawaii, Minnesota, New York (state), Birmingham, Miami, New Mexico, Louisiana, Anchorage, Ohio, Los Angeles, Philadelphia, Houston
Time period: 2003-01-01--2003-12-31
The goal of the Arrestee Drug Abuse Monitoring (ADAM) Program is to determine the extent and correlates of illicit drug use in the population of booked arrestees in local areas. Data were collected in 2003 up to four separate times (quarterly) during the year in 39 metropolitan areas in the United States. The ADAM program adopted a new instrument in 2000 in adult booking facilities for male (Part 1) and female (Part 2) arrestees. The ADAM program in 2003 also continued the use of probability-based sampling for male arrestees in adult facilities, which was initiated in 2000. Therefore, the male adult sample includes weights, generated through post-sampling stratification of the data. For the adult male and female files, variables fell into one of eight categories: (1) demographic data on each arrestee, (2) ADAM facesheet (records-based) data, (3) data on disposition of the case, including accession to a verbal consent script, (4) calendar of admissions to substance abuse and mental health treatment programs, (5) data on alcohol and drug use, abuse, and dependence, (6) drug acquisition data covering the five most commonly used illicit drugs, (7) urine test results, and (8) for males, weights.
Curated
Restricted

Arrestee Drug Abuse Monitoring Program II in the United States, 2007 (ICPSR 25821)

Released/updated on: 2010-01-28
Geographic coverage: North Carolina, Oregon, District of Columbia, Charlotte, Sacramento, Indiana, United States, Chicago, Minnesota, California, New York (state), New York City, Minneapolis, Atlanta, Illinois, Colorado, Portland (Oregon), Denver, Georgia, Indianapolis
Time period: 2007-04-01--2007-09-01
The Arrestee Drug Abuse Monitoring (ADAM) II program was designed to monitor trends in drug use among arrested populations in key urban areas across the United States. The first ADAM data collection was instituted in 2000 as a replacement for the Drug Use Forecasting program (DUF), which employed a non-scientific sampling procedure to select primarily felony arrestees in 23 urban areas throughout the country. The year 2000 revision of ADAM instituted a representative sampling strategy among booked male arrestees in an expanded network of 35 sites. The program was suspended by the National Institute of Justice in 2003 and restarted in 2007 with funding from the Office of National Drug Control Policy (ONDCP). With ADAM II, the ONDCP and Abt Associates have initiated a new data collection that replicates the ADAM methodology in order to obtain data comparable to previously established trends. ADAM II implemented two quarters of data collection in ten sentinel ADAM sites to revive monitoring drug trends, with a particular focus on obtaining valid and reliable information on methamphetamine use. A total of 8,296 arrestees were interviewed during the second and third quarters of 2007. Participation was voluntary and confidential, and the procedures included a personal interview (lasting approximately 20 minutes) and collection of a urine specimen. The Arrestee Drug Abuse Monitoring (ADAM) II survey collected data about drug use, drug and alcohol dependency and treatment, and drug market participation among booked male arrestees within 48 hours of arrest. Demographic variables include age, race, most serious charge, date of arrest, time of arrest, and education level. The data also include whether the provided urine specimen was positive for several drugs including marijuana, cocaine, PCP, methamphetamines, and barbiturates.
Curated
Restricted

Arrestee Drug Abuse Monitoring Program II in the United States, 2008 (ICPSR 27221)

Released/updated on: 2010-03-31
Geographic coverage: North Carolina, Oregon, District of Columbia, Charlotte, Sacramento, Indiana, United States, Chicago, Minnesota, California, New York (state), New York City, Minneapolis, Atlanta, Illinois, Colorado, Portland (Oregon), Denver, Georgia, Indianapolis
The Arrestee Drug Abuse Monitoring (ADAM II) program was designed to monitor trends in drug use among arrested populations in key urban areas across the United States. The first ADAM data collection was instituted in 2000 as a replacement for the Drug Use Forecasting program (DUF), which employed a non-scientific sampling procedure to select primarily felony arrestees in 23 urban areas throughout the country. The year 2000 revision of ADAM instituted a representative sampling strategy among booked male arrestees in an expanded network of 35 sites. The program was suspended by the National Institute of Justice in 2003 and restarted in 2007 with funding from the Office of National Drug Control Policy (ONDCP). With ADAM II, ONDCP and its contractor, Abt Associates Inc. have initiated a new data collection that replicates the ADAM methodology in order to obtain data comparable to previously established trends. ADAM II implements two quarters of data collection in ten sentinel ADAM sites to revive monitoring drug trends, with a particular focus on obtaining valid and reliable information on methamphetamine use. Representing minimal adjustments to the previously employed ADAM survey, the ADAM II survey collects data about drug use, drug and alcohol dependency and treatment, and drug market participation among booked male arrestees within 48 hours of arrest. Data collection has been conducted across two back-to-back quarters in each of 10 counties from a county-based representative sample of 250 male arrestees per quarter for a total of 500 arrestees annually per site or a total of 5,000 arrestees across sites annually. A total of 7,717 arrestees were interviewed during the second and third quarters of 2008. Collection occurs in two cycles in booking facilities at each site to provide estimates for two calendar quarters each year. Data in this file were collected beginning April 1, 2007 and ending March 31, 2008. Additional data collection periods were optioned by ONDCP, and subsequent cycles of back-to-back data collection (not yet available) began April 1, 2008. Participation is voluntary and confidential, and the procedures include a personal interview (lasting approximately 20 minutes) and collection of a urine specimen. Demographic variables include age, race, most serious charge, date of arrest, time of arrest, and education level. The data also include whether the provided urine specimen was positive for several drugs including marijuana, cocaine, PCP, methamphetamines, and barbiturates.
Curated
Restricted

Arrestee Drug Abuse Monitoring Program II in the United States, 2009 (ICPSR 30061)

Released/updated on: 2011-02-24
Geographic coverage: North Carolina, Oregon, District of Columbia, Charlotte, Sacramento, Indiana, United States, Chicago, Minnesota, California, New York (state), New York City, Minneapolis, Atlanta, Illinois, Colorado, Portland (Oregon), Denver, Georgia, Indianapolis
The Arrestee Drug Abuse Monitoring (ADAM II) program was designed to monitor trends in drug use among arrested populations in key urban areas across the United States. The first ADAM data collection was instituted in 2000 as a replacement for the Drug Use Forecasting program (DUF), which employed a non-scientific sampling procedure to select primarily felony arrestees in 23 urban areas throughout the country. The year 2000 revision of ADAM instituted a representative sampling strategy among booked male arrestees in an expanded network of 35 sites. The program was suspended by the National Institute of Justice in 2003 and restarted in 2007 with funding from the Office of National Drug Control Policy (ONDCP). With ADAM II, ONDCP and its contractor, Abt Associates Inc., initiated a new data collection that replicated the ADAM methodology in order to obtain data comparable to previously established trends. ADAM II implemented two quarters of data collection in ten sentinel ADAM sites to revive monitoring drug trends, with a particular focus on obtaining valid and reliable information on methamphetamine use. Representing minimal adjustments to the previously employed ADAM survey, the ADAM II survey collected data about drug use, drug and alcohol dependency and treatment, and drug market participation among booked male arrestees within 48 hours of arrest. A total of 7,794 arrestees were interviewed during the second and third quarters of 2009. Collection occurred in two cycles in booking facilities at each site to provide estimates for two calendar quarters each year. Data in this file were collected beginning April 1, 2009, and ending September 30, 2009. Participation was voluntary and confidential, and the procedures included a personal interview (lasting approximately 20 minutes) and collection of a urine specimen. Demographic variables include age, race, most serious charge, date of arrest, time of arrest, and education level. The data also include whether the provided urine specimen was positive for several drugs including marijuana, cocaine, PCP, methamphetamines, and barbiturates.
Curated
Restricted

Arrestee Drug Abuse Monitoring Program II in the United States, 2010 (ICPSR 32321)

Released/updated on: 2011-11-04
Geographic coverage: North Carolina, Oregon, District of Columbia, Charlotte, Sacramento, Indiana, United States, Chicago, Minnesota, California, New York (state), New York City, Minneapolis, Atlanta, Illinois, Colorado, Portland (Oregon), Denver, Georgia, Indianapolis
The Arrestee Drug Abuse Monitoring (ADAM II) program was designed to monitor trends in drug use among arrested populations in key urban areas across the United States. The first ADAM data collection was instituted in 2000 as a replacement for the Drug Use Forecasting program (DUF), which employed a non-scientific sampling procedure to select primarily felony arrestees in 23 urban areas throughout the country. The year 2000 revision of ADAM instituted a representative sampling strategy among booked male arrestees in an expanded network of 35 sites. The program was suspended by the National Institute of Justice in 2003 and restarted in 2007 with funding from the Office of National Drug Control Policy (ONDCP). With ADAM II, ONDCP and its contractor, Abt Associates Inc., initiated a new data collection that replicated the ADAM methodology in order to obtain data comparable to previously established trends. ADAM II implemented two quarters of data collection in ten sentinel ADAM sites to revive monitoring drug trends, with a particular focus on obtaining valid and reliable information on methamphetamine use. Representing minimal adjustments to the previously employed ADAM survey, the ADAM II survey collected data about drug use, drug and alcohol dependency and treatment, and drug market participation among booked male arrestees within 48 hours of arrest. A total of 8,332 arrestees were interviewed during the second and third quarters of 2010. Collection occurred in two cycles in booking facilities at each site to provide estimates for two calendar quarters each year. Data in this file were collected beginning April 1, 2010, and ending September 30, 2010. Participation was voluntary and confidential, and the procedures included a personal interview (lasting approximately 20 minutes) and collection of a urine specimen. Demographic variables include age, race, most serious charge, date of arrest, time of arrest, and education level. The data also include whether the provided urine specimen was positive for several drugs including marijuana, cocaine, PCP, methamphetamines, and barbiturates.
Curated
Simple Crosstabs

The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] (ICPSR 36575)

Released/updated on: 2017-08-08
Geographic coverage: North Carolina, Milwaukee, Indiana, Ocean (New Jersey), Fort Worth, Cincinnati, Austin, Monmouth (New Jersey), Utah, San Jose, Rock Hill, Gastonia, San Diego, Columbus (Ohio), Syracuse, Springfield (Massachusetts), North Little Rock (Arkansas), Arizona, Las Vegas, Arlington, Springfield (Ohio), Boston, San Bernardino, Providence, Seattle, Kentucky, St. Petersburg, Bethlehem, Niagara Falls (New York), Nashville, California, Florida, Delaware, Hunterdon (New Jersey), Boca Raton (Florida), Troy, Knoxville, Mississippi, Fresno, New Haven, Sarasota, Illinois, Newark, Georgia, Little Rock, Virginia, Maryland, Norfolk, Virginia Beach, Suffolk County (New York), United States, Oklahoma, Grand Rapids, Louisville, Waukesha (Wisconsin), Arkansas, Washington, South Carolina, Albany (New York), Wichita, Mesa (Arizona), Carlisle (Pennsylvania), Fall River, Massachusetts, Missouri, Winston-Salem, Holland (Michigan), New Orleans, Scranton, Denver, Salt Lake City, Harrisburg, Dallas, St. Louis, Nevada, Schenectady, Allentown, Raleigh, San Antonio, Muskegon, St. Paul, Clearwater, Hawaii, Rochester (New York), Passaic, Ventura (California), Birmingham, Michigan, Lebanon, Baltimore, New Mexico, Orlando, Louisiana, Toledo, Middlesex (New Jersey), Philadelphia, Riverside, Oklahoma City, Akron, Greensboro, Detroit, Charlotte, High Point, Tucson, Albuquerque, Everett, Oakland, Bakersfield, New York City, Somerset (New Jersey), Petersburg, Memphis, Ogden, Jacksonville, Buffalo, Pittsburgh, Nassau (New York), Orange County (California), Sacramento, El Paso, Greenville, Kansas, Meriden, Pennsylvania, Tulsa, Chapel Hill (North Carolina), West Palm Beach, Iowa, Texas, Lorain, Portland (Oregon), Hazleton, Tampa, Durham, San Marcos (Texas), Indianapolis, Richmond, Oregon, Warwick, Bergen (New Jersey), Newport News, Ann Arbor, Alabama, Cleveland, Dayton, Nebraska, Omaha, Warren, West Virginia, Elyria, Tacoma, Minneapolis, Youngstown, Atlanta, Honolulu, Phoenix, Bradenton, Wilmington (Delaware), Gary, District of Columbia, Rhode Island, Vancouver (Washington), Lodi (California), Chicago, Fort Lauderdale, Wilkes-Barre, Minnesota, Kansas City (Missouri), Bellevue, New York (state), Anderson, New Jersey, Miami, San Francisco, Charleston (South Carolina), Jersey City, Long Beach, Spartanburg (South Carolina), New Hampshire, Easton, Ohio, Los Angeles, Hartford, Stockton, Houston
Time period: 1990-01-01--2013-01-01

The Community Vulnerability and Responses to Drug-User-Related HIV/AIDS, 1990-2013 [96 Metropolitan Statistical Areas, United States] study (CVAR) was a research study of why large United States Metropolitan Statistical Areas (MSAs) vary over time in their vulnerability to HIV/AIDS among drug users and in MSA responses to HIV/AIDS. This collection contains estimates of HIV prevalence among people who injected drugs (PWID) and among sub-populations of PWID. This collection is comprised of ten datasets with differing amounts of variables and provides trend data that describe the following:

  • Epidemiologic outcomes including population prevalence of PWIDs and Non-injecting drug users (NIDUs), and particularly their prevalence among youth; and, among PWIDs, HIV prevalence, late-diagnosis HIV cases, and AIDS incidence and mortality.
  • Implementation of evidence-based drug-related interventions including drug abuse treatment, syringe exchange, HIV counseling and testing.
  • Implementation of non-evidence-based drug-related interventions including incarceration and arrests of drug users.

The collection contains data on the MSA sub-populations including Black, Hispanic, White and "other" race categories. In addition, some statistics are presented in age range categories such as ages 15-29, 30-64 and 15-64.

Curated
Restricted

Crack, Powder Cocaine, and Heroin: Drug Purchase and Use Patterns in Six Cities in the United States, 1995-1996 (ICPSR 2564)

Released/updated on: 2012-08-22
Geographic coverage: New York City, Oregon, District of Columbia, San Diego, San Antonio, United States, Chicago, Illinois, Texas, Portland (Oregon), California, New York (state)
Time period: 1995-01-01--1996-01-01
This study was designed to address the practical and policy implications of various drug market participation patterns. In 1995, the Office of National Drug Control Policy (ONDCP) and the National Institute of Justice (NIJ) collaborated on a project called the Procurement Study. This study was executed as an addendum to NIJ's Drug Use Forecasting (DUF) program (DRUG USE FORECASTING IN 24 CITIES IN THE UNITED STATES, 1987-1997 [ICPSR 9477]) with the goal of extending previous research in which heroin users were interviewed on various aspects of drug market activity. The present study sought to explore additional features of drug market participation and use, both within and across drug types and cities, and included two additional drugs -- powder cocaine and crack cocaine. Data were collected from recently arrested users of powder cocaine, crack cocaine, and heroin in six DUF cities (Chicago, New York, Portland, San Diego, San Antonio, and Washington, DC). Each of the three files in this collection, Crack Data (Part 1), Heroin Data (Part 2), and Powder Cocaine Data (Part 3), is comprised of data from a procurement interview, urine test variables, and a DUF interview. During the procurement interview, information was collected on purchase and use patterns for specific drugs. Variables from the procurement interview include the respondent's method of using the drug, the term used to refer to the drug, whether the respondent bought the drug in the neighborhood, the number of different dealers the respondent bought the drug from, how the respondent made the connection with the dealer (i.e., street, house, phone, beeper, business/store, or friends), their main drug source, whether the respondent went to someone else if the source was not available, how the respondent coped with not being able to find drugs to buy, whether the respondent got the drug for free, the means by which the respondent obtained money, the quantity and packaging of the drug, and the number of minutes spent searching for, traveling to, and waiting for their last purchase. Urine tests screened for the presence of ten drugs, including marijuana, opiates, cocaine, PCP, methadone, benzodiazepines (Valium), methaqualone, propoxyphene (Darvon), barbiturates, and amphetamines (positive test results for amphetamines were confirmed by gas chromatography). Data from the DUF interview provide detailed information about each arrestee's self-reported use of 15 drugs. For each drug type, arrestees were asked whether they had ever used the drug, the age at which they first used the drug, whether they had used the drug within the past three days, how many days they had used the drug within the past month, whether they had ever needed or felt dependent on the drug, and whether they were dependent on the drug at the time of the interview. Data from the DUF interview instrument also included alcohol/drug treatment history, information about whether arrestees had ever injected drugs, and whether they were influenced by drugs when the crime that they were charged with was committed. The data also include information about whether the arrestee had been to an emergency room for drug-related incidents and whether he or she had had prior arrests in the past 12 months. Demographic data include the age, race, sex, educational attainment, marital status, employment status, and living circumstances of each respondent.
Curated

Monitoring Drug Epidemics and the Markets That Sustain Them, Arrestee Drug Abuse Monitoring (ADAM) and ADAM II Data, 2000-2003 and 2007-2010 (ICPSR 33201)

Released/updated on: 2012-12-13
Geographic coverage: North Carolina, Oregon, District of Columbia, Charlotte, Sacramento, Indiana, United States, Chicago, Minnesota, California, New York (state), New York City, Minneapolis, Atlanta, Illinois, Colorado, Portland (Oregon), Denver, Georgia, Indianapolis
Time period: 2000-01-01--2003-01-01, 2007-01-01--2010-01-01
This study examined trends in the use of five widely abused drugs among arrestees at 10 geographically diverse locations from 2000 to 2010: Atlanta, Charlotte, Chicago, Denver, Indianapolis, Manhattan, Minneapolis, Portland Oregon, Sacramento, and Washington DC. The data came from the Arrestee Drug Abuse Monitoring Program reintroduced in 2007 (ADAM II) and its predecessor the ADAM program. ADAM data included urinalysis results that provided an objective measure of recent drug use, provided location specific estimates over time, and provided sample weights that yielded unbiased estimates for each location. The ADAM data were analyzed according to a drug epidemics framework, which has been previously employed to understand the decline of the crack epidemic, the growth of marijuana use in the 1990s, and the persistence of heroin use. Similar to other diffusion of innovation processes, drug epidemics tend to follow a natural course passing through four distinct phases: incubation, expansion, plateau, and decline. The study also searched for changes in drug markets over the course of a drug epidemic.